Hoofddorp, The Netherlands / Bologna, Italy, 11th August 2026 SEVER Life Sciences B.V. (“SEVER”) today announced that it has signed a Share Purchase Agreement (“SPA”) for the sale of 100% of the shares in Nordic Group B.V. and its subsidiaries (“Nordic Group”) to Alfasigma S.p.A. (“Alfasigma”). The transaction is subject to customary closing conditions, including any required regulatory approvals. Completion […]